Sino Biological Launches AI-Trusted and AI-Qualified Target Protein Collections to Accelerate AI-Driven Discovery

By The Building Texas Show•
Sino Biological introduces two new target protein collections to support AI-driven drug discovery, providing researchers with well-characterized proteins essential for validating AI-designed molecules.

Found this article helpful?

Share it with your network and spread the knowledge!

Sino Biological Launches AI-Trusted and AI-Qualified Target Protein Collections to Accelerate AI-Driven Discovery

HOUSTON, TX – As artificial intelligence continues to transform recombinant protein and antibody discovery for therapeutic and diagnostic development, access to well-characterized target proteins has become critical for evaluating AI-designed molecules. Sino Biological, Inc., a global biotechnology company specializing in recombinant proteins, antibodies, and CRO services, has introduced two dedicated target protein collections for AI-driven discovery: AI-Trusted Proteins and AI-Qualified Proteins. The collections are designed to offer researchers target proteins with demonstrated use in AI research, experimentally characterized binding activity, and specialized formats to support diverse AI-driven validation.

The AI-Trusted Proteins collection includes proteins that have been used in AI-focused company validation projects, with some featured in published research. Currently covering 600+ targets and 960+ individual proteins, the collection provides available characterization data for each protein, potentially including SPR, BLI, ELISA, cell-based activity assays, SEC-HPLC, and SEC-MALS analyses. The AI-Qualified Proteins collection features experimentally characterized target binding activity, including SPR/BLI validation data, as well as specialized formats such as biotinylated proteins for AI-driven research. With 680+ targets and 1,700+ individual proteins, this collection offers a broad selection of characterized target proteins for evaluating AI-designed molecules.

Supporting these collections is Sino Biological’s 4S System—Scale, Scope, Speed, and Supply—designed to provide the resource breadth, production capabilities, and supply reliability required by AI-driven discovery. Scale includes more than 11,000 recombinant target proteins, including over 1,200 biotinylated proteins. Scope covers membrane, extracellular, and intracellular proteins, as well as mutants and diverse protein formats. Speed encompasses rapid, scalable production, efficient order processing, and local inventory and delivery capabilities. Supply ensures lot-to-lot consistency, multi-lot availability, and reliable long-term supply. Together, the 4S System helps researchers access a broad range of target proteins while supporting consistent experimental needs and ongoing AI research programs.

Sino Biological has also developed a therapeutic target directory covering 12 therapeutic areas and more than 100 diseases, enabling researchers to explore relevant targets by therapeutic area or disease. Target proteins are a critical part of experimental validation. As a key resource within Sino Biological’s 4RISE™ AI Lab Validation Solution, the AI-focused target protein library works alongside high-throughput protein expression, binding and affinity characterization, developability assessment, and functional validation. Built around four strengths—Rapid, In-Depth, Seamless, and Empirical—4RISE™ provides integrated wet-lab support to help researchers advance AI-designed molecules from computational predictions to experimental evidence.

“AI-driven discovery depends on reliable experimental resources to evaluate designed molecules and guide subsequent research decisions,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. “By combining AI-Trusted and AI-Qualified target proteins with our 4S System, we aim to provide researchers with well-characterized target resources, broad coverage, and dependable supply to support AI-driven protein and antibody discovery.”

For Texas, the announcement signals a significant boost to the local biotechnology ecosystem. Sino Biological’s US operations are based in Houston, and the expanded target protein collections could accelerate AI-driven drug discovery efforts in the state. Texas has been growing as a hub for life sciences and biotechnology, and access to well-characterized proteins is essential for researchers developing new therapeutics and diagnostics. The new collections may also foster collaborations between Sino Biological and Texas-based research institutions, biotech companies, and academic centers, potentially leading to new jobs and investment in the region. Researchers can learn more about the company and its offerings at www.sinobiological.com, and the original release is available via NEWMEDIAWIRE.